Antimicrobial Resistance (AMR) is one of the leading causes of death around the world. While we work hard to develop new drugs and fix the underlying causes of AMR, it’s vital that we protect the antibiotics we have.
It is with regret that we inform you that the above event has been switched to a virtual-only event. This is in light of pending UK Government Cabinet discussions today regarding potential for implementation of Plan B as early as tomorrow.
York Trials Unit (University of York), in collaboration with Hull University Teaching Hospitals NHS Trust and Hull York Medical School, are calling for expressions of interest from hospitals around the UK to take place in the BioDriveAFS trial. This research is funded by the National Institute for Health Research.
Following the publication of both the English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) report 2020-2021 and its Scottish equivalent, Scottish One Health Antimicrobial Use and Antimicrobial Resistance in 2020, it might be tempting to celebrate the reported fall in the number of deaths in England attributable to antibiotic-resistance (AMR), as well as the overall decline in antibiotic consumption across England and Scotland. Yet we must remember that the ongoing COVID-19 pandemic will have, in all likelihood, distorted the picture.
Initiated in 1999, BSAC’s flagship Antimicrobial Resistance Surveillance Programme amassed a collection of almost 100,000 isolates from a range of clinically significant species, which provided many benefits to the research community and industry sponsors alike.